BeOne Medicines (BEIGF) Cash from Investing Activities Growth (1y) (2016 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Cash from Investing Activities Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | -38.43% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -46.70% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -103.94% |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | -174.44% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 129.18% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 25.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.90% |
| Mar 31, 2026 | 62.68% |
| Dec 31, 2025 | 59.05% |
| Sep 30, 2025 | 63.20% |
| Jun 30, 2025 | 40.01% |
| Mar 31, 2025 | 41.89% |
| Dec 31, 2024 | -49.57% |
| Sep 30, 2024 | 28.13% |
| Jun 30, 2024 | -263.76% |
| Mar 31, 2024 | -187.04% |
| Dec 31, 2023 | -262.40% |
| Sep 30, 2023 | -209.91% |
| Jun 30, 2023 | -89.71% |
| Mar 31, 2023 | 14.58% |
| Dec 31, 2022 | -64.68% |
| Sep 30, 2022 | 1,512.96% |
| Jun 30, 2022 | 161.81% |
| Mar 31, 2022 | -27.93% |
| Dec 31, 2021 | 225.52% |
| Sep 30, 2021 | 99.22% |